Startup list · Global
AI drug discovery startups
Below are the top global AI drug discovery startups, ranked by total funding. Together the 50 companies on this list have raised a combined $23B, and include 22 unicorns. The strongest hubs are United States, United Kingdom, China.
$23Bcombined funding · 50 companies
United Statestop hub
50companies shown
22unicorns
Ranked by total funding · Updated 2026-11-03 · Source: Dealroom
| # | Company | Founded | HQ | Funding |
|---|---|---|---|---|
| 1 |
I
Isomorphic LabsUnicorn
An artificial intelligence company to discover new drugs
|
2021 | London, United Kingdom | $2.7B |
| 2 |
M
MirendilUnicorn
AI models for biology and materials science research
|
2026 | San Francisco, United States | $1.2B |
| 3 |
X
Xaira TherapeuticsUnicorn
Integrated biotechnology company focusing on leveraging artificial intelligence to transform drug discovery and development
|
2023 | South San Francisco, United States | $1.0B |
| 4 |
E
Enveda BiosciencesUnicorn
AI-native biotech discovering oral medicines from life's chemistry
|
2019 | Boulder, United States | $833M |
| 5 |
O
Odyssey Therapeutics
Building a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases
|
2018 | Boston, United States | $792M |
| 6 |
X
XtalPiUnicorn
Artificial intelligence (AI) pharmaceutical firm
|
2014 | Shenzhen, China | $785M |
| 7 |
G
Generate BiomedicinesUnicorn
Pioneering Generative Biology to create breakthrough medicines
|
2020 | Somerville, United States | $693M |
| 8 |
E
ExscientiaUnicorn
Applying artificial intelligence and big data processing to accelerate discovery and development of drugs
|
2012 | Oxford, United Kingdom | $675M |
| 9 |
I
InsitroUnicorn
Insitro is revolutionizing pharmaceutical R&D by leveraging machine learning for drug discovery
|
2018 | San Francisco, United States | $643M |
| 10 |
C
Chai DiscoveryUnicorn
AI-driven foundation models for predicting and reprogramming biochemical molecule interactions, enhancing drug discovery and molecular research
|
2024 | San Francisco, United States | $630M |
| 11 |
R
Recursion PharmaUnicorn
A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery
|
2013 | Salt Lake City, United States | $599M |
| 12 |
L
LifeMine Therapeutics
Pioneering in genomically-enabled drug discovery approach integrating advanced life science and computational technologies
|
2017 | Cambridge, United States | $563M |
| 13 |
L
Lila SciencesUnicorn
Scientific superintelligence to tackle humanity's greatest challenges through AI-driven discovery and innovation
|
2022 | Cambridge, United States | $550M |
| 14 |
R
Relay TherapeuticsUnicorn
A new breed of company at the intersection of computation and biotechnology that is committed to creating medicines that will have a transformative impact on patients
|
2016 | Cambridge, United States | $550M |
| 15 |
I
InSilico MedicineUnicorn
Develops an AI platform for drug development to treat cancer and age-related diseases
|
2014 | Cambridge, United States | $532M |
| 16 |
F
Formation BioUnicorn
Technology company that helps bring treatments to patients faster
|
2013 | New York City, United States | $530M |
| 17 |
V
Valo HealthUnicorn
Cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process
|
2019 | Lexington, United States | $488M |
| 18 |
G
Genuity Science
Genomic information company using sequence data to improve health for people around the world
|
2013 | Boston, United States | $455M |
| 19 |
B
BenevolentAIUnicorn
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company
|
2013 | London, United Kingdom | $454M |
| 20 |
M
METiS TherapeuticsUnicorn
AI-driven platform for drug discovery and delivery
|
2017 | Cambridge, United States | $405M |
| 21 |
G
Genesis Molecular AI$25M+ revenueDealroom profile unavailable
Unifying AI and Biotech We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines
|
2019 | San Mateo, United States | $400M |
| 22 |
S
Schrodinger
Computational drug designing for pharmaceutical and biotechnology research
|
1990 | New York City, United States | $373M |
| 23 |
O
OwkinUnicorn
Collaborative research platform and unique AI drug development solutions that make precision medicine a reality
|
2016 | Paris, France | $335M |
| 24 |
A
Alto NeuroscienceDealroom profile unavailable
Clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform
|
2019 | Los Altos, United States | $307M |
| 25 |
A
Arbor Biotechnologies
Diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability
|
2016 | Cambridge, United States | $305M |
| 26 |
I
Iambic Therapeutics
AI-driven chemistry for medicine
|
2019 | San Diego, United States | $303M |
| 27 |
I
ImmunaiUnicorn
Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes
|
2019 | New York City, United States | $301M |
| 28 |
C
ConcertAIUnicorn
Accelerating insights and outcomes for patients through leading RWD, AI technology and scientific expertise
|
2017 | Cambridge, United States | $300M |
| 29 |
H
Huma$25M+ revenue
Provides a digital health platform used for predictive care and research
|
2011 | London, United Kingdom | $298M |
| 30 |
B
BioAge Labs
BIOAGE discovers and develops drugs to treat aging and associated diseases
|
2015 | Emeryville, United States | $294M |
| 31 |
A
Anew LabsDealroom profile unavailable
ByteDance-spun AI drug discovery for oral small-molecule immunology
|
2026 | Yangpu District, China | $290M |
| 32 |
S
Soley Therapeutics
Drug discovery and development company using cellular responses and AI to identify novel therapies for complex diseases
|
2020 | Brentwood, United States | $290M |
| 33 |
G
Gritstone Oncology
Developing next-generation personalized cancer therapeutics
|
2015 | Emeryville, United States | $261M |
| 34 |
P
PathAI
AI-powered pathology platform optimizing diagnostic accuracy and research
|
2016 | Boston, United States | $259M |
| 35 |
F
Frontier Medicines
Frontier Medicines, a South San Francisco, CA-based new pre-clinical stage biopharmaceutical company
|
2018 | South San Francisco, United States | $256M |
| 36 |
B
Berkeley Lights$25M+ revenue
BL is enabling cell by cell selection & manipulation to empower development, antibody discovery and engineering for personalized therapies
|
2011 | Emeryville, United States | $246M |
| 37 |
D
Deep Genomics
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies
|
2014 | Toronto, Canada | $237M |
| 38 |
S
Seismic Therapeutic
The Machine Learning Immunology Company
|
2020 | Watertown, United States | $231M |
| 39 |
A
AbSciUnicorn
The global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry
|
2011 | Vancouver, United States | $228M |
| 40 |
B
bit.bio
Developing a scalable technology platform capable of producing consistent batches of every human cell
|
2016 | Cambridge, United Kingdom | $225M |
| 41 |
M
Monte Rosa TherapeuticsUnicorn
Developing next-generation small molecule protein degraders to treat cancer and beyond
|
2018 | Boston, United States | $224M |
| 42 |
B
Basecamp Research
AI protein and therapeutic design from biodiversity-scale genomic data
|
2019 | London, United Kingdom | $220M |
| 43 |
W
Warp SciencesFast growingDealroom profile unavailable
AI- and robotics-driven chemistry labs providing drug discovery services to biotech and pharma
|
2026 | South San Francisco, United States | $215M |
| 44 |
S
Superluminal MedicinesFast growing
Generative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created
|
2023 | Boston, United States | $213M |
| 45 |
A
Achilles Therapeutics
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
|
2016 | Stevenage, United Kingdom | $208M |
| 46 |
A
Asimov
Synthetic biology company building tools to design living systems
|
2017 | Boston, United States | $205M |
| 47 |
S
Stealth StartupDealroom profile unavailable
Developing AI models for drug discovery, including tools to identify new uses for existing and failed medicines
|
2026 | San Francisco, United States | $200M |
| 48 |
P
Predictive Oncology
A leader in functional precision medicine harnessing the power of tumor to personalize therapy
|
2002 | Pittsburgh, United States | $198M |
| 49 |
T
Terray Therapeutics
Terray Therapeutics – A New Paradigm in Drug Discovery
|
2018 | Pasadena, United States | $195M |
| 50 |
S
Scipher Medicine
Bringing precision medicine to complex diseases through the power of network medicine
|
2015 | Waltham, United States | $192M |
Track AI drug discovery startups worldwide
Get the full dataset — funding rounds, investors, signals and new entrants — in the Dealroom platform.
Book a demo
















































